Pharmacokinetics of two formulations of omeprazole administered through a gastrostomy tube in patients with severe neurodevelopmental problems.

@article{Boussery2011PharmacokineticsOT,
  title={Pharmacokinetics of two formulations of omeprazole administered through a gastrostomy tube in patients with severe neurodevelopmental problems.},
  author={Koen Boussery and J. Wim De Smet and Pieter de Cock and S Vande velde and Els Mehuys and Peter de Paepe and Jean Paul Remon and Jan F P Van Bocxlaer and Myriam A Van Winckel},
  journal={British journal of clinical pharmacology},
  year={2011},
  volume={72 6},
  pages={990-6}
}
AIMS Omeprazole is often administered through a gastrostomy tube as either (i) a Multiple Unit Pellet System (MUPS®) tablet disintegrated in water (MUPS® formulation), or (ii) a suspension in 8.4% sodium bicarbonate (suspension formulation). This bioavailability study evaluates this practice in tube-fed patients with severe neurodevelopmental problems. METHODS Nonblinded, two-phase cross-over trial. RESULTS In seven of 10 patients, bioavailability was higher for the suspension formulation… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 19 references

Omeprazole pharmacodynamics and gastric acid suppression in critically ill pediatric transplant patients.

Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies • 2001

Similar Papers

Loading similar papers…